Form 4: BIO-TECHNE Director Amy Herr Boosts Equity Holdings
Insider Transaction Report
BIO-TECHNE Director Amy Herr reported the acquisition of 1,640 common shares and 3,777 stock options, alongside existing indirect holdings.
Summary
- Director Amy E. Herr acquired 1,640 shares of BIO-TECHNE Corp common stock at a price of $0 on October 30, 2025.
- Herr also acquired 3,777 stock options with an exercise price of $60.96 at a price of $0 on October 30, 2025.
- These newly acquired stock options will vest on the earlier of October 30, 2026 (one-year anniversary of grant) or the date of Bio-Techne's 2026 annual meeting of shareholders, and expire on October 30, 2035.
- Following these transactions, Herr directly owns 2,680 common shares and 3,777 stock options.
- Herr also indirectly holds 2,154 common shares and various derivative securities (stock options and restricted stock units) through a significant other, with various vesting and expiration dates extending through 2035.
Sentiment
Score: 7
Explanation: The acquisition of common stock and stock options by a director, particularly at a $0 price, suggests a positive outlook from insider management and increases their vested interest in the company's future performance.
Positives
- Director Amy E. Herr acquired 1,640 shares of common stock at $0, increasing direct equity ownership.
- Director Amy E. Herr acquired 3,777 stock options at $0, indicating future potential equity upside and aligning interests with shareholders.
Future Outlook
The newly acquired stock options for Amy E. Herr will vest on the earlier of October 30, 2026, or the date of Bio-Techne's 2026 annual meeting of shareholders. Various other indirectly held stock options and restricted stock units have vesting schedules extending through 2028 and expiration dates as late as 2035, indicating a long-term incentive structure.
Industry Context
NA
Related Party Transactions
- Indirect beneficial ownership of 2,154 common shares and various derivative securities (stock options and restricted stock units) by a significant other of Amy E. Herr.
Stakeholder Impact
- Shareholders: Increased alignment of a director's interests with shareholders due to increased equity ownership and potential future equity.
Next Steps
- Vesting of 3,777 stock options on the earlier of October 30, 2026, or the date of Bio-Techne's 2026 annual meeting of shareholders.
- Ongoing vesting of various indirectly held stock options and restricted stock units according to their respective schedules, extending through 2028.
Key Dates
| Date | Description |
|---|---|
| 10/24/2025 | Expiration date for 2,415 stock options with an exercise price of $72.05. |
| 10/30/2025 | Date of acquisition for 1,640 common shares and 3,777 stock options. |
| 11/03/2025 | Date of signature by Attorney-in-Fact for Amy E. Herr. |
| 02/03/2026 | Vesting date for 86 stock options (indirect) and 38 restricted stock units (indirect). |
| 08/07/2026 | Expiration date for 6,636 fully vested stock options (indirect) with an exercise price of $47.6. |
| 08/15/2026 | Vesting date for 524 shares from stock options (indirect), 271 shares from stock options (indirect), 367 shares from stock options (indirect), 118 restricted stock units (indirect), 160 restricted stock units (indirect), 311 restricted stock units (indirect), and 912 shares from stock options (indirect). |
| 10/30/2026 | Vesting date for 3,777 newly acquired stock options or the date of Bio-Techne's 2026 annual meeting of shareholders. |
| 02/03/2027 | Vesting date for 86 stock options (indirect) and 38 restricted stock units (indirect). |
| 08/05/2027 | Expiration date for 4,472 fully vested stock options (indirect) with an exercise price of $66.97. |
| 08/15/2027 | Vesting date for 271 shares from stock options (indirect), 367 shares from stock options (indirect), 160 restricted stock units (indirect), 311 restricted stock units (indirect), and 912 shares from stock options (indirect). |
| 02/03/2028 | Vesting date for 86 stock options (indirect) and 39 restricted stock units (indirect). |
| 08/06/2028 | Expiration date for 2,076 fully vested stock options (indirect) with an exercise price of $120.46. |
| 08/15/2028 | Vesting date for 367 shares from stock options (indirect), 310 restricted stock units (indirect), and 911 shares from stock options (indirect). |
| 02/03/2029 | Vesting date for 86 stock options (indirect). |
| 08/15/2029 | Expiration date for 2,104 stock options (indirect) with an exercise price of $94.52. |
| 08/15/2030 | Expiration date for 1,084 stock options (indirect) with an exercise price of $84.61. |
| 08/15/2034 | Expiration date for 1,468 stock options (indirect) with an exercise price of $74.91. |
| 02/03/2035 | Expiration date for 2,415 stock options (direct) and 344 stock options (indirect) with an exercise price of $72.05. |
| 08/15/2035 | Expiration date for 2,735 stock options (indirect) with an exercise price of $53.6. |
| 10/30/2035 | Expiration date for 3,777 newly acquired stock options with an exercise price of $60.96. |
Recommendation
holdThe acquisition of common stock and stock options by a director indicates insider confidence in the company's future prospects. However, this filing is a routine disclosure of insider transactions and does not provide comprehensive financial or operational data to warrant a 'buy' or 'sell' recommendation. It serves as a positive signal that should be considered alongside broader financial analysis.
Keywords
BIO-TECHNE, TECH, Form 4, Insider Transaction, Director, Stock Options, Common Stock, Equity Acquisition, Beneficial Ownership, Amy Herr
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.